View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 18, 2022

Sernova and Evotec collaborate to develop cell therapy for diabetes

Evotec made a $15.7m strategic equity investment in Sernova and will also invest another $5.25m.

Sernova has signed an exclusive worldwide strategic collaboration with Evotec for developing a cell therapy for treating individuals with insulin-dependent diabetes. 

Under the partnership, the companies will merge and use their respective technologies and scientific capabilities for developing an implantable induced pluripotent stem cells (iPSC)-based beta cell replacement therapy. 

This therapy is intended to offer unrestricted insulin-producing cell source for the treatment of people with insulin-dependent diabetes.

The deal will integrate the Cell Pouch System technologies of Sernova with Evotec’s iPSC-based beta cells. 

Integrating ethically derived, insulin-producing beta cells of Evotec into Sernova’s Cell Pouch platform offers the potential to deliver a ‘functional cure’ for patients with diabetes through an off-the-shelf product, which is cGMP-controlled and scalable.

As per the collaboration, Sernova will hold a worldwide exclusive option for licencing iPSC-based beta cells of Evotec for the treatment of type 1 and type 2 diabetes. 

Furthermore, Evotec made a $15.7m (€15m) strategic equity investment in Sernova and intends to invest another $5.25m (€5m). 

Evotec chief scientific officer Dr Cord Dohrmann will become part of the board of directors of Sernova, as part of the agreement and investment.

The companies will fund the preclinical development programme(s) jointly until obtaining clearance for the Investigational New Drug (IND) application. 

Following IND submission, Sernova can exercise its option for an exclusive worldwide licence. 

Evotec will offer its cell manufacturing expertise for the research, development and marketing of the product and will make a decision on the joint financing of clinical development in the future. 

On marketing, Sernova and Evotec will have a profit-sharing arrangement contingent on the participation of Evotec in the clinical development programme’s funding.

Dohrmann said: “Together we will progress a highly differentiated first-in-class beta cell therapy into clinical development with the common goal to bring a truly transformative therapy to insulin-dependent diabetic patients. 

“The synergies of Evotec’s and Sernova’s technologies puts Sernova in position to become the world’s leader in beta cell replacement therapy.”

In January this year, Evotec and Eli Lilly and Company and entered a drug discovery collaboration within the metabolic diseases field, with a focus on kidney diseases and diabetes.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology